XT
BCAX

XTX Topco’s Bicara Therapeutics BCAX Stock Holding History

XTX Topco’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,067
Closed -$573K – 4523
2025
Q4 		$573K Sell
34,067
-3,707
-10% -$63.3K 0.02% 1478
2025
Q3 		$596K Buy
37,774
+5,360
+17% +$60K 0.03% 939
2025
Q2 		$301K Buy
32,414
+3,961
+14% +$47.2K 0.01% 1433
2025
Q1 		$371K Buy
28,453
+1,119
+4% +$14.9K 0.02% 1249
2024
Q4 		$476K Buy
+27,334
New +$569K 0.04% 803

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

XTX Topco's BCAX Position: Q1 2026 in Review

XTX Topco sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 34,067 shares — an estimated $573K sold.

XTX Topco first reported a position in BCAX in Q4 2024 and held it in 5 quarters. The position peaked at $596K in Q3 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • XTX Topco reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 34,067 Bicara Therapeutics shares in Q1 2026, an estimated $573K.
  • XTX Topco first reported a position in Bicara Therapeutics in Q4 2024 and held it in 5 quarters.
  • XTX Topco's Bicara Therapeutics position peaked at $596K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.